In vivo microdialysis studies of somatodendritic dopamine release in the rat substantia nigra: Effects of unilateral 6-OHDA lesions and GDNF

Experimental Neurology

Volumn 147, Issue 1, 1997, Pages 130-141

  Hoffman, Alexander F ^a   Van Horne, Craig G ^b   Eken, Servet ^a   Hoffer, Barry J ^a   Gerhardt, Greg A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; APOMORPHINE; DEXAMPHETAMINE; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HOMOVANILLIC ACID; OXIDOPAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE RELEASE; MALE; MICRODIALYSIS; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

EID: 0031239557     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1997.6571     Document Type: Article

References (43)

1. Arenas E., Trupp M., Akerud P., Ibanez C. F. GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. Neuron. 15:1995;1465-1473.
2. Benveniste H., Huttemeier P. C. Microdialysis - Theory and application. Prog. Neurobiol. 35:1990;195-215.
3. Bjorklund A., Lindvall O. Dopamine in dendrites of substantia nigra neurons: Suggestions for a role in dendritic terminals. Brain Res. 83:1975;531-537.
4. Bowenkamp K. E., David D., Lapchak P. L., Henry M. A., Granholm A. C., Hoffer B. J., Mahalik T. J. 6-Hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat - A possible mechanism for restoration of the nigrostrial circuit mediated by glial cell line-derived neurotrophic factor. Exp. Brain Res. 111:1996;1-7.
5. Bowenkamp K. E., Hoffman A. F., Gerhardt G. A., Henry M. A., Biddle P. T., Hoffer B. J., Granholm A. C. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J. Comp. Neurol. 355:1995;479-489.
6. Carman L. S., Gage F. H., Shults C. W. Partial lesion of the substantia nigra: Relation between extent of lesion and rotational behavior. Brain Res. 553:1991;275-283.
7. Cass W. A., Zahniser N. R., Flach K. A., Gerhardt G. A. Clearance of exogenous dopamine in rat dorsal striatum and nucleus accumbens: Role of metabolism and effects of locally applied uptake inhibitors. J. Neurochem. 61:1993;2269-2278.
8. Cheramy A., Leviel V., Glowinski J. Dendritic release of dopamine in the substantia nigra. Nature. 289:1981;537-542.
9. Church W. H., Justice J. B. Jr. Rapid sampling and determination of extracellular dopamine in vivo. Anal. Chem. 59:1987;712-716.
10. Dunnett S. B., Robbins T. W. The functional role of mesotelencephalic dopamine systems. Biol. Rev. Cambridge Philos. Soc. 67:1992;491-518.
11. Hall M., Hoffer B., Gerhardt G. Rapid and sensitive determination of catecholamines in small tissue samples by high pressure liquid chromatography coupled with dual-electrode coulometric electrochemical detection. LC-GC. 7:1989;258-265.
12. Heeringa M. J., Abercrombie E. D. Biochemistry of somatodendritic dopamine release in substantia nigra: An in vivo comparison with striatal dopamine release. J. Neurochem. 65:1995;192-200.
13. Herrera-Marschitz M., Ungerstedt U. Evidence that striatal efferents relate to different dopamine receptors. Brain Res. 323:1984;269-278.
14. Hoffer B. J., Hoffman A., Bowenkamp K., Huettl P., Hudson J., Martin D., Lin L. F., Gerhardt G. A. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 182:1994;107-111.
15. Hoffman A. F., Van Horne C. G., Gerhardt G. A., Hoffer B. J. Deficits in spontaneous locomotor activity in the unilaterally 6-hydroxydopamine-lesioned rat. Soc. Neurosci. Abstr. 21:1995;225.6.
16. Hokfelt T., Martensson A., Bjorklund A., Kleinau S., Goldstein M. Distributional maps of tyrosine-hydroxylase-immunoreactive neurons in the rat brain. Handbook of Chemical Neuroanatomy. 1984;Elsevier, New York. p. 387-406.
17. Hornykiewicz O., Kish S. J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45:1987;19-34.
18. Hudson J., Granholm A. C., Gerhardt G. A., Henry M. A., Hoffman A., Biddle P., Leela N. S., Mackerlova L., Lile J. D., Collins F. Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res. Bull. 36:1995;425-432.
19. Hudson J. L., Levin D. R., Hoffer B. J. A 16-channel automated rotometer system for reliable measurement of turning behavior in 6-hydroxydopamine lesioned and transplanted rats. Cell Transplant. 2:1993;507-514.
20. Hudson J. L., Van Horne C. G., Stromberg I., Brock S., Clayton J., Masserano J., Hoffer B. J., Gerhardt G. A. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res. 626:1993;167-174.
21. Kilpatrick I. C., Starr M. S., Fletcher A., James T. A., Macleod N. K. Evidence for a GABAergic nigrothalamic pathway in the rat. I. Behavioural and biochemical studies. Exp. Brain Res. 40:1980;45-54.
22. Lapchak P. A., Miller P. J., Jiao S. S., Araujo D. M., Hilt D., Collins F. Biology of glial cell line-derived neurotrophic factor (GDNF): Implications for the use of GDNF to treat Parkinson's disease. Neurodegeneration. 5:1996;197-205.
23. Leenders K. L., Aquilonius S. M., Bergstrom K., Bjurling P., Crossman A. R., Eckernas S. A., Gee A. G., Hartvig P., Lundqvist H., Langstrom B. Unilateral MPTP lesion in a rhesus monkey: Effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers. Brain Res. 445:1988;61-67.
24. Leenders K. L., Salmon E. P., Tyrrell P., Perani D., Brooks D. J., Sager H., Jones T., Marsden C. D., Frackowiak R. S. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch. Neurol. 47:1990;1290-1298.
25. Lin L. F., Doherty D. H., Lile J. D., Bektesh S., Collins F. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 260:1993;1130-1132.
26. Lin L. F., Zhang T. J., Collins F., Armes L. G. Purification and initial characterization of rat B49 glial cell line-derived neurotrophic factor. J. Neurochem. 63:1994;758-768.
27. Lindsay R. M., Altar C. A., Cedarbaum J. M., Hyman C., Wiegand S. J. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease. Exp. Neurol. 124:1993;103-118.
28. McCown T. J., Mueller R. A., Breese G. R. Effects of anesthetics and electrical stimulation on nigrostriatal dopaminergic neurons. J. Pharmacol. Exp. Ther. 224:1983;489-493.
29. Norman A. B., Wyatt L. M., Hildebrand J. P., Kolmonpunporn M., Moody C. A., Lehman M. N., Sanberg P. R. Sensitization of rotation behavior in rats with unilateral 6-hydroxydopamine or kainic acid-induced striatal lesions. Pharmacol. Biochem. Behavior. 37:1990;755-759.
30. Opacka-Juffry J., Ashworth S., Hume S. P., Martin D., Brooks D. J., Blunt S. B. GDNF protects against 6-OHDA nigrostriatal lesion: In vivo study with microdialysis and PET. Neuroreport. 7:1995;348-352.
31. Orosz D., Bennett J. P. Simultaneous microdialysis in striatum and substantia nigra suggests that the nigra is a major site of action ofL. Exp. Neurol. 115:1992;388-393.
32. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, New York.
33. Perlow M. J., Freed W. J., Hoffer B. J., Seiger A., Olson L., Wyatt R. J. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science. 204:1979;643-647.
34. Price M. L., Hoffer B. J., Granholm A. C. Effects of GDNF on fetal septal forebrain transplantsin oculo. Exp. Neurol. 141:1996;181-189.
35. Robertson G. S., Damsma G., Fibiger H. C. Characterization of dopamine release in the substantia nigra by in vivo microdialysis in freely moving rats. J. Neurosci. 11:1991;2209-2216.
36. Robertson G. S., Robertson H. A. Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms. J. Neurosci. 9:1989;3326-3331.
37. Robinson T. E., Mocsary Z., Camp D. M., Whishaw I. Q. Time course of recovery of extracellular dopamine following partial damage to the nigrostriatal dopamine system. J. Neurosci. 14:1994;2687-2696.
38. Santiago M., Westerink B. H. Characterization and pharmacological responsiveness of dopamine release recorded by microdialysis in the substantia nigra of conscious rats. J. Neurochem. 57:1991;738-747.
39. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 367:1971;69-93.
40. Ungerstedt U., Arbuthnott G. W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 24:1970;485-493.
41. Van Horne C., Hoffer B. J., Stromberg I., Gerhardt G. A. Clearance and diffusion of locally applied dopamine in normal and 6-hydroxydopamine-lesioned rat striatum. J. Pharmacol. Exp. Ther. 263:1992;1285-1292.
42. Warenycia M. W., McKenzie G. M. Excitation of striatal neurons by dexamphetamine is not abolished by either chloral hydrate or urethane anaesthesia. Neuropharmacology. 27:1988;1309-1312.
43. You Z. B., Nylander I., Herrera-Marschitz M., O'Connor W. T., Goiny M., Terenius L. The striatonigral dynorphin pathway of the rat studied with in vivo microdialysis - I. Effects of K(+)-depolarization, lesions and peptidase inhibition. Neuroscience. 63:1994;415-425.